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Abstract
The individual risk for common diseases not only depends on genetic but also on epigenetic polymorphisms. To assess the
role of epigenetic variations in the individual risk for obesity, we have determined the methylation status of two CpG islands
at the POMC locus in obese and normal-weight children. We found a hypermethylation variant targeting individual CpGs at
the intron2–exon3 boundary of the POMC gene by bisulphite sequencing that was significantly associated with obesity.
POMC exon3 hypermethylation interferes with binding of the transcription enhancer P300 and reduces expression of the
POMC transcript. Since intron2 contains Alu elements that are known to influence methylation in their genomic vicinity, the
exon3 methylation variant seems to result from an Alu element–triggered default state of methylation boundary definition.
Exon3 hypermethylation in the POMC locus represents the first identified DNA methylation variant that is associated with
the individual risk for obesity.
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Introduction
Inter-individual variations of epigenetic modifications like CpG
methylation can alter gene function and may play a role as an
individual risk for common diseases like obesity [1]. In contrast to
the nucleotide sequence of DNA, the level and distribution of CpG
methylation can change during development and aging as shown
by the increasing differences in DNA methylation in monozygotic
twins over lifetime [2,3]. This dynamic feature of DNA
methylation has focussed the interest of current research on the
potential environmental impact on DNA modification as one
molecular mechanism that might transmit the phenomenon of
early programming [4]. However, the majority of the methylome
remains remarkably stable despite aging and differences in the
environment [5–7]. Therefore it seems likely that the methylome
varies between individuals and can influence the individual risk for
diseases. Since these stable patterns are established early during
development and before the separation of germ layers [8,9] they
are similar in different tissues and cell types and can be identified
in a representative manner by the use of easy accessible DNA from
peripheral blood cells (PBC) [10].
Recent genome wide methylation studies in DNA from PBC
identified the first inter-individual variations of methylation that
correlate with the phenotype BMI [11]. These variants represent
regions of different CpG island methylation (‘‘variably methylated
regions, VMR’’) [11]. Because even a single CpG methylation
difference can have a strong impact on gene transcription under
some circumstances [12] a large number of small methylation
differences in single CpGs might be present in the genome aside
from VMRs and might account for an obese phenotype. In order
to identify such obesity-associated single CpG variants we used a
classical candidate gene approach. Candidate genes with potential
obesity associated epigenetic variants can be deduced from
patients with monogenetic obesity.
In most patients with early-onset monogenetic obesity, muta-
tions were found that reduce the dose of signals in the anorexigenic
leptin pathway within the arcuate nucleus, including the leptin-
responsive gene preproopiomelanocortin (POMC) [13]. In addi-
tion, genome wide association studies (GWA) revealed several
single nucleotide polymorphisms (SNP) among others in the
POMC gene locus that was associated with obesity phenotypes
[14]. Moreover mutations in the POMC gene are dependent on the
gene dosage [15]. Together these genetic evidences for a dosage
sensitive role of POMC in the pathogenesis of obesity made us to
choose the POMC gene as a candidate to search for CpG
methylation variants that might correlate with childhood obesity.
Results
DNA methylation of the POMC locus in normal weight
individuals
The POMC gene contains three exons. The functionally relevant
peptides ACTH, MSH and beta-endorphin are cleaved from the
C-terminal part of the protein that is translated from the exon 3
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sequence [16]. Different POMC transcripts were described within
the major population initiated via the promoter proximal to exon
1 and some smaller, less well-described variants that might be
transcribed from alternative 39 transcription start sites [17,18].
Two CpG islands have been identified within the POMC gene
located at the 59-promoter-region and around the intron 2 and
exon 3 boundary (Figure 1). To estimate the stability of the CpG
methylation pattern within these islands, we initially compared
different POMC expressing tissues and DNA samples taken from
healthy individuals at different ages.
Bisulphite sequencing of DNA samples from peripheral blood
cells (PBC) of 12 normal weight adolescent individuals revealed
distinct DNA methylation patterns at both CpG islands. At the 59-
promoter CpG island an overall hypomethylation was found with
some reproducible methylation peaks before exon 1 which were
most prominent at position 220 to 222 and 227 to 230. The
second 39 CpG island was characterized by a particularly sharp
shift from hypermethylation in intron 2 to hypomethylation in
exon 3 at the 39-CpG island (Figure 1 and Figure 2).
In PBCs the POMC gene is expressed and its function has been
analysed in different immune cells. Moreover, both, the short and
long POMC transcript variants have been described in PBCs [19–
21]. We subsequently investigated the POMC gene methylation
pattern in a second cell type that expresses the gene within the
context of body weight regulation. DNA was derived from MSH-
positive neurons of the human hypothalamic arcuate nucleus after
laser-microdissection of post-mortem hypothalamic specimen [22]
(Figure 2). We found the identical pattern as in DNA from PBC.
CpG island 1 was mainly hypomethylated with the same peaks of
methylation at position 220 to 222 and 227 to 230 and the
same sharp change in CpG island 2 of hypermethylation in intron
2 to a hypomethylation in exon 3 was present (Figure 2).
Finally we investigated the stability of POMC CpG-methylation
during life. We compared the pattern in adolescent PBC DNA
with the pattern in DNA derived from newborn (PBC-DNA from
Guthrie spots). In all samples we found the identical methylation
pattern in CpG island 1 and 2 irrespective of the age of the
probands (Figure 2). Since we found the identical methylation
pattern of POMC CpG islands in PBCs at different ages and in
arcuate nucleus cells, both deriving from different germ layers and
both expressing the POMC gene in different functional contexts,
we concluded that the identified particular methylation pattern is
set very early during development and is stable irrespective of the
physiological function of the cells.
DNA hypermethylation in obese patients
After having identified a region of stable DNA methylation in
the POMC gene in normal healthy individuals, we set out to
identify POMC gene methylation variants that are enriched in the
obese childhood population. We compared the POMC gene
methylation pattern in DNA derived from PBC of obese and
normal weight children. The two cohorts did not differ in their age
or gender distribution and the range of obesity was from +2,1 to
+6,9 standard deviation scores of body mass index (SDS-BMI)
[23]. Only obese children were included in whom POMC gene
mutations had already been excluded.
Using DNA samples of 71 obese and 36 normal weight children
we observed the identical pattern of CpG island 1 methylation in
all children irrespective of their BMI (data not shown). In CpG
island 2 we found a difference of methylation in obese children
showing an extension of the intron 2 hypermethylation into the
normally hypomethylated exon 3 (Figure 3A, Figure S1). Because
we observed a certain level of variability at each CpG position in
CpG island 2 in this large number of individuals we further
confirmed the individual reproducibility of the methylation
profiles by examining the intra-individual variability and stability
of the methylation status. We analysed the DNA methylation of
different PCR amplifications and different blood samples of either
two normal weight or two obese individuals, in whom a
hypermethylated variant had been identified (Figure S2). We
found an intra-individual variability at the 3- and 5- border of
differential methylated region that affects one or two single CpG
positions. These intra-individual differences were smaller com-
pared to the inter-individual differences of the two normal weight
versus the two obese patients. In order to define a ‘‘hypermethyla-
tion variant’’ even further despite this intra-individual variability at
single CpG positions, we calculated the overall methylation score
of the variable region rather then analysing single CpG positions
separately. We included the most variable positions of the region
being the last four 39-CpG positions of intron 2 and the first six 59-
CpG positions of exon 3 (Figure 3). The resulting overall CpG
methylation score from position 24 to +6 was calculated in all
children of the cohort and revealed a significant difference in obese
versus normal weight children (25% versus 40%) (p,0.001)
(Figure 3B). The most prominent difference of a single CpG
position was found at position +1 where only 5% of normal weight
children but 55% of obese children showed methylation
(Figure 3C).
To confirm these results, we performed a second independent
case-control study based on an alternative bisulphite sequencing
protocol (direct sequencing, see Text S1) in additional 100 obese
and 54 normal weight children. We found the same methylation
variant of CpG island 2 with a highly significant difference in the
overall methylation score of position 24 to +6 in normal weight
(23%) versus obese (32%) children (p,0.001) (Figure 3D–3F).
Based on the intra-individual methylation variability and the
observed differences of the overall methylation score at CpG
island 2 in the two different cohorts, that might be related to and
further enhanced by the different bisulphite sequencing methods, a
‘‘hypermethylation variant’’ versus a ‘‘hypomethylation variant’’
can only be defined by statistical means. We therefore calculated
the percentiles of methylation score in the24 to +6 region of CpG
island 2 in the two normal weight children cohorts. We found a
level of 56% methylation score as the 95th percentile of overall
methylation in cohort 1 and of 36% in cohort 2. Using the 95th
percentile of methylation score in the normal weight controls as a
Author Summary
Twin studies reveal a strong genetic background of body-
weight regulation. However, gene mutations in early onset
obesity patients are rare. Results from large genome-wide
association studies explain less than 4% of body-weight
variability. Therefore, other mechanisms like epigenetic
alterations may play a role in body-weight regulation. We
analysed the DNA methylation of the POMC gene, which
plays a central role in body-weight regulation within the
hypothalamus. We observed a significant increase in the
methylation score in obese children as compared to
normal-weight individuals. This DNA methylation variant
affects POMC gene dosage regulation. Therefore we
conclude that this DNA hypermethylation variant in obese
patients leads by modification of POMC gene expression to
an increased individual risk for the development of
obesity. This result illustrates how DNA methylation
alterations increase the susceptibility to a common disease
like obesity.
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cut-off level for a ‘‘hypermethylation variant’’, 30% of the obese
children versus 5% of normal weight children within the first
cohort were found to have the ‘‘hypermethylation variant’’.
In order to exclude additional genetic differences that might
cause the observed methylation variants, the POMC intron 2 -
exon 3 regions were sequenced and genotyped for all known SNPs
in the POMC locus in all individuals. No further genetic mutations
could be identified in the intron 2-exon 3 region and no significant
correlation between the individual SNPs and DNA methylation
pattern was detected (Figure S3).
The POMC hypermethylation variant is established early
in life
Several studies have indicated that DNA methylation might
change during life due to environmental influences. Even though
we identified identical POMC methylation patterns in DNA from
normal weight newborns and adolescents - which is a strong
argument for the stability of early established patterns - we cannot
rule out that the methylation variant observed in obese children
may be a consequence of obesity. Therefore, we analysed the
POMC DNA methylation pattern in a longitudinal birth cohort
(Multicenter Allergy Study, MAS) [24], which was initiated in
1990 and followed up until 2010. Participants of this study were
followed from birth up to 20 years of age and DNA samples were
available for the age of 5, 13 and 20 years. We focussed on those
individuals, who were of normal weight at 5 and 13 years and
became obese at the age of 13 or 20 years. In 21 of these cases
DNA material was still available from these time points. In 8 of
these individuals we identified the same POMC hypermethylated
variant of exon 3 that we had already found in the two obese
cohorts studied before. Based on the previous results we defined a
‘‘hypermethylated variant’’ as having a methylation score above
the 95th percentile of the DNA methylation of the normal weight
control groups, which in our case was 36%. The cut-off value was
chosen because the same bisulphite sequencing protocol was used.
In all 8 individuals hypermethylation was already present prior to
the development of obesity (Figure 4). In one case the DNA
methylation score decreased up to the age of 20 years – however,
this DNA methylation score was still in the upper range. Overall
the degree of methylation (position 24 to +6) did not change
during the 16 years period of obesity manifestation. These data of
the MAS cohort participants strongly suggest that the hyper-
methylation variant of the POMC gene represents an early-
established DNA methylation ‘‘signature’’ that occurs early in life
in a subset of patients and might increase the risk for obesity rather
than representing a consequence of obesity.
Novel promoter activity of the POMC intron 2–exon 3
region in vitro
A strong association of the exon 3 hypermethylation variant
with the obese phenotype suggests an influence of this variant on
POMC gene expression or function. In principle, methylation of
CpGs interferes with the accessibility of the DNA for proteins that
modulate chromatin and gene transcription. In studies from the
early 1990th the 39region of the POMC gene including the exon 3
hypermethylation sequence was discussed to probably represent an
Figure 1. POMC CpGmethylation pattern of CpG island 1 and 2. Analysis example of the DNA methylation pattern of human peripheral blood
cells (PBC) from a normal weight individual after sequencing of 10 different clones of the PCR amplification product. Filled cycles represent
methylated CpGs, open cycles non-methylated CpG positions, which are numbered according to their relative position to the start of the next exon.
Alu element positions and P300 binding site are marked.
doi:10.1371/journal.pgen.1002543.g001
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alternative promoter for short POMC transcripts in different tissues
[17]. Moreover, in this region a sequence fitting the guidelines of
Kozak has been identified that would allow translation of a shorter
protein including the functional relevant MSH peptides
[17,18,25]. Whether short POMC transcripts are translated into
functional peptides is still matter of a controversial debate and the
results of different studies have been contradictory [21,26–30].
However, in peripheral blood cells both the long and the short
transcript variant have been identified [19,20]. Despite these data
the promoter activity of this intron 2-exon 3 region has not been
investigated.
Therefore we analysed the promoter activity of this 39 POMC
region by using a POMC intron 2-exon3 construct in a CpG free
luciferase vector [31] (kindly provided by M. Rehli, Regensburg,
Germany). The functional assay was performed with a GT 1-7
hypothalamic mouse cell line. We observed an increased luciferase
activity of the intron 2-exon 3 containing vector compared to the
negative control, suggesting a potential promoter activity of this
POMC region (Figure S4). Most importantly, following treatment
of the 53 CpG sites containing construct with the CpG
methyltransferase SssI the transcriptional activity of the intron 2-
exon 3 construct was diminished. Together these data suggest a so
far unrecognized transcriptional activity of the intron 2-exon 3
region within the POMC gene that can be inhibited by
hypermethylation.
Exon 3 hypermethylation, P300 complex binding, and
POMC gene expression
In order to further characterize a potential role for exon 3
hypermethylation in controlling POMC gene function we tried to
identify proteins that might bind to the 39 promoter and that could
be inhibited by methylation at positions +1 to +5 of exon 3. By in
silico analysis (http://www.cbil.upenn.edu/cgi-bin/tess/tess) we
found that the intron 2 – exon 3 junction contains a putative
binding site for the histone acetyltransferase P300 complex in mice
and humans, which is involved in chromatin acetylation and gene
activation [32,33] (Figure 5A). In order to confirm these in silico
data we performed a chromatin-immune-precipitation (ChIP)
assay. A specific binding of P300 to the POMC exon 3 in DNA
from human PBC DNA could be demonstrated (Figure 5B). We
Figure 2. POMC DNA methylation pattern of CpG island 1 and 2 in normal-weight adolescents (n=12), laser-microdissected MSH
positive cells of the human arcuate nucleus (n=5) and human newborn samples (n=8). CpG positions are numbered according to their
relative position to the next exon start.
doi:10.1371/journal.pgen.1002543.g002
POMC Hypermethylation in Childhood Obesity
PLoS Genetics | www.plosgenetics.org 4 March 2012 | Volume 8 | Issue 3 | e1002543
used a published P300 binding site within the insulin promoter as a
positive control experiment (Figure S5) [34]. The P300 binding
site in exon 3 is localized directly 39 adjacent to the sequence with
the most intense hypermethylation at CpG-position +1 in obese
children (Figure 5A). Therefore we hypothesized, that hyper-
methylation in obese children at position +1 interferes with P300
binding and subsequently reduces POMC expression. We tested
this hypothesis by analysing the P300 binding capacity with ChIP
in PBC of 4 obese patients with the POMC hypermethylation
variant (mean DNA methylation score 45%64 at CpG position
24 to 6) compared to 6 normal weight individuals (mean DNA
methylation score 25%65 at CpG position 24 to 6). By real-time
PCR analysis of the ChIP products, we observed a significantly
reduced P300 binding (Figure 5C), indicating that hypermethyla-
tion might affect binding of the P300 complex. Because P300 is a
member of an acetyltransferase complex its reduced binding in
Figure 3. The DNA methylation was analysed with two different bisulphite based protocols in two independent cohorts. A, B, C
agarose-embedded DNA was analysed by bisulphite sequencing. In D, E, F DNA was bisulphite treated in a non-agarose-bead protocol. A/D Diagram
of the DNA methylation score (%) of POMC CpG island 2 within PBC of normal weight (red) and obese individuals (blue) (p,0,001). CpG positions are
numbered according to their relative position to the next exon start. B/E Box plots analysis represents the statistic differences from the mean CpG
methylation score (%) of CpG position 24 to +6 in normal weight individuals versus obese patients. C/F Percent of normal weight (red) and obese
(blue) individuals, who showed DNA methylation at the annotated single CpG position (21 to +5) in relation to the analysed number of samples.
doi:10.1371/journal.pgen.1002543.g003
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hypermethylation will influence more likely the regulation of
complex chromatin function rather then local promoter activity of
the intron-2 region. To asses the impact of the hypermethylation
variant on POMC gene expression we performed real time RT-
PCR of POMC products from PBC in 20 hypermethylated obese
patients (mean DNA methylation score 48%66 at CpG position
24 to 6) compared to 20 normal weight control individuals (mean
DNA methylation score 25%65 at CpG position 24 to 6) and 20
obese patients without the POMC hypermethylated variant (mean
DNA methylation score 30%65 at CpG position24 to 6). In PBC
with the hypermethylation variant we observed a significantly
reduced PCR product of a fragment that covers exon3 alone as
well as a fragment that covers exon2 and exon3 (Figure 5D).
Because the longer fragment, that covers exon2 and exon3
represents a transcript that is transcribed from the 59 promoter of
the POMC gene, we conclude that the hypermethylation variant
interfere at least in part with the transcription of the functionally
relevant and well known long transcript containing the signal
peptide and the coding region for the melanocortin peptides.
However, whether an additional influence of the hypermethylation
variant on a shorter 39 transcript exists, cannot be excluded.
Potential molecular origin of the exon 3 POMC
hypermethylation variant
The results of our functional assays suggest that P300 binding to
the 59 sequence of exon 3 is critical for POMC gene expression and
that methylation of exon 3 CpGs seems to interfere with P300
binding. Consequently we hypothesized that for POMC gene
expression exon 3 CpGs need to remain hypomethylated in
different species that contain a P300 binding site around CpG
position +1. To verify this assumption we investigated the
methylation status of the second CpG island as well as the
nucleotide sequence of the intron 2-exon 3 region in mice.
Comparison of the human and mice POMC locus revealed the
predicted phylogenetically conserved hypomethylation of exon 3
in mice. Surprisingly, in contrast to the human methylation
pattern, the murine intron 2-sequence is not methylated at all
(Figure 6A, 6D). Further comparison of the murine and human
intron 2 sequences revealed a difference in the locus structure in
that the human intron 2 contains three Alu elements (Figure 1),
which are not present in mice [35]. The presence of Alu elements
within intron 2 in our cohorts was confirmed by sequencing
analysis of all samples (data not shown). Because Alu elements are
known to alter the methylation pattern in their genomic vicinity
[36,37] we further hypothesized that the POMC intron 2
hypermethylation in humans is caused by the presence of the
Alu elements within intron 2. We tested this hypothesis by
bisulphite sequencing of the POMC intron 2-exon 3 region from
different primates, since Alu elements are only present in primate
genomes, however to a different extent [38]. We found, that
primates - like the chimpanzees - with the same Alu elements as
the human sequence share the same human DNA methylation
pattern of intron 2 hypermethylation and exon 3 hypomethylation
(Figure 6B). In contrast, in DNA from more distant primates - like
lemurs - who do not contain Alu elements in intron 2, we found a
complete hypomethylation of intron 2 (Figure 6C) as in the Alu
element-free mouse POMC gene.
These data from mouse, human, and other primate POMC gene
loci show a close association between the presence of Alu elements
in intron 2 with the state of hypermethylation of intron 2 CpGs
suggesting that the Alu elements in intron 2 may trigger
methylation. Because hypomethylation of exon 3 seems to be
critical for POMC gene expression one can speculate, that in species
with Alu elements the hypomethylation state of exon 3 needs to be
defended against an Alu element triggered intron 2 methylation
force. In this scenario Alu element triggered intron 2 methylation
needs to be restricted with a sharp border at the first 59 CpGs of
exon 3. The hypermethylation variant of these first 59-CpGs of exon
3 would therefore represent a default state of methylation restriction
with an extension of intron 2 methylation into exon3.
Discussion
During the last few years a large number of highly powered
GWA studies were conducted to identify genetic variants that
Figure 4. Longitudinal analysis of POMC DNA methylation score (%) (CpG position 24 to +6) before and after the development of
obesity in altogether 21 participants of the MAS birth cohort. Each line represents one individual course of DNA methylation score prior to
and after weight gain.
doi:10.1371/journal.pgen.1002543.g004
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correlate with an increased genetic risk for obesity [14]. Despite
the successful identification of several SNPs that influence the
individual body weight, their overall impact on the weight
phenotype variation was estimated to be less than 4% [39,40].
Therefore, other inter-individual variants of the chromatin like
epigenetic polymorphisms need to be considered as a further
determinant for the individual body weight phenotype.
POMC methylation has been analysed in different studies
before. Hence, a methylation dependent POMC promoter activity
has been described in-vitro [41]. Moreover altered POMC promoter
methylation has been observed in different tumor cell-lines, which
was accompanied by changes in POMC gene expression [41,42].
Finally, reduced POMC methylation has been identified in fetal
hypothalamic samples from offspring after maternal undernutri-
tion in sheep, which was attended by increased POMC gene
expression [43,44]. The latter study provides the most explicit
evidence for an interrelation between metabolism and epigenetic
regulation of the POMC gene in mice, which was further supported
recently in another animal study [45].
We now describe the first epigenetic variant in the POMC gene
in humans being highly associated with severe obesity in children.
The hypermethylation variant affects only a few distinct single
CpG-sites at the border of a hypermethylation stretch in intron 2.
Upon increased methylation in obese children, methylation
extended this CpG-hypermethylated region into the non-methyl-
ated exon 3.
Hypomethylation of exon 3 is highly conserved in different
species suggesting a functional relevance of an open chromatin
state of this POMC region. Accordingly, we could demonstrate a
reduced binding of the transcription enhancer P300 to its binding
site in direct proximity to the methylation variant and we could
show a reduced level of POMC transcripts in PBC with the
hypermethylation variant. Moreover the hypermethylation variant
leads to a reduced mRNA expression of the long POMC transcript
containing exon2 and exon3, which suggests that the 59 promoter
of the POMC gene can be indirectly influenced by the methylation
state of the intron2-exon3 39 region. Together these findings argue
that the intron2-exon3 region might function as an enhancer for
the 59 POMC promoter transcription.
Genome-wide studies of DNA methylation patterns showed a
reduced methylation density at P300 binding sites. The latter are
predominantly located at gene activating elements and display an
increased monomethylation of H3K4, which indicates an open
chromatin formation [33,46]. However, a transcriptional regula-
tory activity of the intron 2-exon 3 region of the POMC gene was
not described before, despite the fact that several studies have
identified smaller POMC transcripts. These are not transcribed
from the 59 POMC promoter, but are rather likely to originate
from the intron 2 region. We could now show a transcription
activity of the intron 2-exon 3 fragment of the human POMC gene
in a luciferase reporter construct. The activity could be blocked by
pre-treatment with the CpG methyltransferase SssI. Together
these data strongly suggest that the POMC gene region containing
the hypermethylation variant is relevant for POMC gene
transcription and that methylation can interfere with this
transcriptional activity and function of the POMC gene. Because
we could further show a reduced expression of the long transcript
containing exon2 and exon3 it seems reasonable that the
hypermethylation variant reduces an enhancer activity of the
intron2-exon3 region that act on the 59 promoter. Therefore the
association of the hypermethylation variant with obesity results
from a reduced expression of the functional relevant long POMC
transcript containing the signal peptide and the weight regulating
melanocortin peptides by interfering with a 39 enhancer of the
POMC gene. However, it cannot be excluded that in addition a
shorter POMC transcript that originates from the intron2-exon3
region is affected by the hypermethylation variant.
The CpG methylation variant is associated with body weight,
but was detected in DNA from peripheral blood leucocytes, which
do not participate in weight regulation. Therefore, it is tempting to
speculate that the variant in blood cells reflects a non tissue-specific
general methylation pattern that is also present within POMC
expressing cells in which it plays a role in the weight regulatory
pathway. We have shown that the overall methylation pattern of
CpG island 2 is very stable in different cell types, including POMC
expressing cells of the arcuate nucleus as well as during the
individual lifetime and in different primate species. Hence, the
individual pattern of CpG island 2 methylation seems to be
established early during development and remains stable in
different cell types irrespective of age and environment. We
postulate that this stability within different cells and lifetime
periods also exists for the obesity-associated hypermethylation
variant of CpG island 2, because obese individuals with the variant
have been shown to harbour the hypermethylation pattern of CpG
island 2 already before the onset of obesity at a young age.
However, due to obvious ethical reasons we could not finally prove
the presence of the variant in the critical hypothalamic arcuate
nucleus neurons of obese patients.
While hypomethylation of exon 3 is conserved in all species
tested, including mice, we found the hypermethylation of intron 2
only in the genomes of primates who contain Alu-elements. Alu
elements derive from retrotransposons and are known to trigger
methylation in their genomic vicinity presumably to reduce
transcriptional activity of the retrotransposomal DNA [47]. It is
tempting to speculate that the methylation of Alu elements and
other retrotransposons during early development may stochasti-
cally spread into adjacent regions. This is similar to position-effect
variegation in Drosophila, although over much shorter distances,
and these patterns are then stably transmitted to daughter cells
during further development [48]. In this respect, the hypermethy-
lation variant in POMC exon 3 would result from an Alu-triggered
methylation force that is usually restricted to intron 2, but may
extend to the first CpG of exon 3 in terms of a border demarcation
weakness. Due to the transcriptional activity of this exon 3
sequence the Alu-triggered hypermethylation may affect POMC
expression and influence the risk for obesity. Such epigenetically
controlled transcriptional interference by transposons has been
described before in several inherited diseases such as X-linked
dystonia-parkinsonism [49] and in several organisms [50],
including the agouti viable yellow mice [51]. In these examples
Figure 5. POMC intron2 exon3 genomic sequence, P300 ChIP assay, real-time PCR analysis, and real-time POMC PCR. (A) POMC intron2
exon3 genomic sequence with annotated ChIP primer localization and P300 binding site. (B) P300 ChIP assay was performed at three independent
occasions within human peripheral blood cells. POMC fragment was amplified with two different primer pairs (fragment 1 and 2). Confirmation of a
published P300 binding site within the insulin gene promoter in b-TC3 cells was used as a positive control [34] (Figure S5). (C) Real time PCR analysis
(PCR fragment 2) of the P300 ChIP results of 4 obese patients with a hypermethylation variant and 6 individuals with hypomethylated intron 2-exon 3
intersection at POMC CpG island 2. (D) Real-time POMC PCR (POMC exon 2–3 and POMC exon3) of cDNA extracted from PBC of hypomethylated
normal weight individuals (n = 20), hypermethylated obese patients (n = 20), and obese individuals without the hypermethylated variant (n = 20)
reveal reduced POMC gene expression in the hypermethylated samples.
doi:10.1371/journal.pgen.1002543.g005
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Figure 6. Species-specific POMC methylation pattern POMC DNA methylation pattern after bisulphite genomic sequencing of CpG
island 2. In (A) normal-weight human individuals (n = 36), (B) chimpanzee PBC (n = 2), (C) lemur PBC (n = 3), and (D) mice PBC (n = 3). CpG positions
are numbered according to their relative position to the exon 3 start.
doi:10.1371/journal.pgen.1002543.g006
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the transposon changed its position and represents a genetic first
hit that is followed by the epigenetic secondary change with
pathological consequences. However, the identified POMC
hypermethylation variant was not associated with a genomic
rearrangement of the Alu elements or with any other genetic
difference. From that point of view we presume that this POMC
methylation variant is a stochastically occurring mistake in the
termination of Alu element-triggered methylation leading to a
potentially pathologic individual ‘‘epigenetic signature’’. The
molecular mechanism that regulates the exact border restriction
of CpG-methylation is unknown. Therefore we cannot exclude,
that another genetic variant exists in trans, outside the POMC
locus, that interferes with an appropriate methylation border
restriction and thus may influence the border definition of intron
2-methylation in terms of a primary genetic defect.
An epigenetic contribution to the pathogenesis of obesity has
been widely discussed and predicted. In our study we demonstrate
now for the first time an epigenetic variant of CpG methylation in
the candidate gene POMC that seems to be functionally relevant
for gene expression and that is enriched in obese children
compared to normal weight individuals.
Materials and Methods
Ethics statement
All clinical investigations and genetic analysis were performed
according the guidelines of the Declaration of Helsinki and with
the agreement of all family members and the ethic committee of
the Charite´ Virchow-Klinikum.
Patients, controls, post-mortem brain samples, cell lines,
mice, and primate DNA samples
The DNA samples of patients were collected at the obesity
outpatient clinic of the Institute of Experimental Paediatric
Endocrinology at the Charite´ Children’s Hospital in Berlin.
DNA, extracted from human peripheral blood cells (Qiagen),
was analysed from normal weight individuals (55 female and 35
male, average age 17,9 years, average BMI=18,59 kg/m
2), and in
obese children in whom POMC gene mutation was excluded (91
female and 80 male, average age 11 years, average
BMI= 32,3 kg/m
2). Cohort 1: 36 normal weight individuals
(female:male = 25:11, average age 18,4 years, average BMI
19 kg/m
2); 71 obese individuals (female:male = 35:36, average age
13,2 years, average BMI 31,2 kg/m
2); cohort 2: 54 normal weight
individuals (female:male = 30:24, average age 17,4 years, average
BMI 18,2 kg/m
2); 100 obese individuals (female:male = 56:44,
average age 8,8 years, average BMI 33,4 kg/m
2). DNA extracted
from PBC of 21 participants of the MAS birth cohort [24] was
analysed at the age of 5 or 13 years of age (average
BMI= 16,04 kg/m
2) before the development of obesity and at the
age of 13 or 20 years (average BMI=27,49 kg/m
2) after the onset
of obesity longitudinally. Rolland-Cachera-BMI percentiles were
used to define obesity as a BMI above the 97. percentile [23].
DNA from newborn screening cards was extracted according to
standard protocols (Promega). For the analysis of the newborn
blood samples parents gave special informed consent.
Brain samples were obtained from autopsies in a period of
,24 h post-mortem, which were performed according to the law
of Berlin (Sektionsgesetz, Gesetz- und Verordnungblatt fu¨r Berlin,
1996; 52 32, 237–239). Subjects were selected with no history of
neurological diseases (2 female, 3 male, average age 73,4 years,
average BMI= 29,6 kg/m
2).
The pancreatic cell line b-TC3 was kindly provided by the
group of J. Seufert (Freiburg, Germany). b-TC3-cells and GT 1-7
cells, were maintained in DMEM-medium (Invitrogen) supple-
mented with 10% fetal bovine serum, penicillin (100 U/ml),
streptomycin (100 mg/ml) and l-glutamin (2 mM).
Mice peripheral blood cells have been obtained from a C57BL/
6 mice strain (kindly provided by J. Koehrle, Berlin, Germany).
Primate blood samples have been obtained from the Deutsches
Primatenzentrum (DPZ, Go¨ttingen, Germany).
DNA methylation analysis
DNA methylation was analysed according to standard protocols
[52] with agarose embedded DNA or in the second independent
cohort with direct bisulphite treated DNA. Details of both
methods and cohorts are available in Text S1. The laser-
microdissected cells were analysed as described [53].
Postmortem human brain tissue, immunohistochemistry,
and laser microdissection
Human brain samples were cut into 10 mm sections and stained
with the beta-MSH antibody (G. Brabant, Birmingham, UK).
Immunohistochemical analysis of Beta-MSH of human arcuate
nucleus was carried out as previously described [22]. Further
information is available in Text S1. MSH positives cells of the
arcuate nucleus were extracted by laser microdissection (ZEISS).
Luciferase reporter-gene assay
The luciferase assays were performed according standard protocols
(Dual luciferase reporter assay, Promega) with a pCpGL-vector
(kindly gift from M. Rehli, Regensburg, Germany) [31] in GT1-7
mouse hypothalamic cells. The POMC CpG island 2 fragment was
created with a BamH1 and Nco1 restriction recognition site. In vitro
methylation was performed with a 16 h incubation of the transfected
construct (0.5 mg) with Sss1 (NEB, Promega). The transfected
construct without added SAM to the enzymatic reaction serves as a
negative control. Primer sequences are available in the Text S1.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed with DNA extracted from
peripheral blood cells of patients with and without the hyper-
methylated POMC variant. Samples were preincubated with
magnetic beads (Invitrogen) for 1 h (+4uC). Thereafter the samples
were transferred to P300 antibody (N-15, Santa Cruz) labelled
magnetic beads and incubated overnight on a tilting table. Finally
the samples were incubated for 16 hours at 65uC and the final
PCR was performed with two different primer pairs after ethanol
washing steps. As a negative control the samples were also
incubated with magnetic beads and anti-FLAG antibody (SIGMA)
as well as non-antibody labelled magnetic beads. For detailed
description of the ChIP protocol see Text S1.
Quantitative real-time PCR
RNA was extracted from 2 ml EDTA blood samples using the
Trizol method. These samples were collected prospectively from
20 normal weight controls and 20 obese individuals with or
without the hypermethylation variant. DNAse digestion and
cDNA synthesis was performed according standard protocols
(NEB, Promega). Quantitative real time PCR reactions for ß-actin
as a housekeeping gene and POMC were established according to
standard protocols. For detailed description of the quantitative real
time PCR and primer sequence see Text S1.
Statistical analysis
To compare the degree of DNA methylation score between
obese and non-obese persons the mean DNA methylation of CpG
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for the positions 24 to +6 was used as a test variable in a t-Test. A
linear regression model with the mean DNA methylation of CpG
for the positions 24 to +6 as dependent variable and age, sex and
BMI standard deviation score BMI-SDS as independent variables
were calculated in order to estimate the influence of BMI-SDS on
mean DNA methylation of CpG positions 24 to +6.
Supporting Information
Figure S1 A Sequence example with genomic sequence of a
hypomethylated POMC intron 2 exon 3 boundary of a normal
weight individual (B) and an obese patient with a hypermethylated
POMC variant (C).
(PDF)
Figure S2 Analysis of the intra-individual variability of the
POMC DNA methylation at the intron2-exon3 intersection. DNA
methylation was analysed from two normal weight individuals and
two obese individuals with the hypermethylated variant. The DNA
was extracted from three different blood samples of each
individual (A, B, C) and three independent PCR amplification
reactions were performed with each DNA sample.
(PDF)
Figure S3 Diagram of the observed SNPs (No1-6) within the
POMC gene in correlation to the observed DNA methylation
intensity at CpG position 24 to +6 of the individual respectively.
(PDF)
Figure S4 Luciferase reporter-gene assay with a POMC CpG
island 2 fragment. A schematic display of the fragment localization
B Luciferase assay with empty pCpGL vector, pCpGL_CpG
island 2 vector treated with Sss1 or treated with Sss1 without SAM
addition as a control. The luciferase activity is annotated
according the luciferase/renilla ratio of 3 independent experi-
ments.
(PDF)
Figure S5 P300 ChIP analysis of the insulin promoter with
samples of b-TC3 beta-cells. We used this published P300 binding
site [34] as positive control for the established ChIP assay.
(PDF)
Text S1 A summary of the different bisulphite sequencing
protocols used in this study. Moreover the primer pair sequences
and the different protocols for ChIP and qPCR experiments are
described in detail.
(DOC)
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